Skip to main content

Advertisement

SpringerLink
Log in

Up-regulation of SNCA gene expression: implications to synucleinopathies

  • Review Article
  • Published:
neurogenetics Aims and scope Submit manuscript

Abstract

Synucleinopathies are a group of neurodegenerative diseases that share a common pathological lesion of intracellular protein inclusions largely composed by aggregates of alpha-synuclein protein. Accumulating evidence, including genome wide association studies, has implicated alpha-synuclein (SNCA) gene in the etiology of synucleinopathies. However, the precise variants within SNCA gene that contribute to the sporadic forms of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and other synucleinopathies and their molecular mechanisms of action remain elusive. It has been suggested that SNCA expression levels are critical for the development of these diseases. Here, we review several model systems that have been developed to advance the understanding of the role of SNCA expression levels in the etiology of synucleinopathies. We also describe different molecular mechanisms that regulate SNCA gene expression and discuss possible strategies for SNCA down-regulation as means for therapeutic approaches. Finally, we highlight some examples that underscore the relationships between the genetic association findings and the regulatory mechanisms of SNCA expression, which suggest that genetic variability in SNCA locus is directly responsible, at least in part, to the changes in gene expression and explain the reported associations of SNCA with synucleinopathies. Future studies utilizing induced pluripotent stem cells (iPSCs)—derived neuronal lines and genome editing by CRISPR/Cas9, will allow us to validate, characterize, and manipulate the effects of particular cis-genetic variants on SNCA expression. Moreover, this model system will enable us to compare different neuronal and glial lineages involved in synucleinopathies representing an attractive strategy to elucidate—common and specific—SNCA-genetic variants, regulatory mechanisms, and vulnerable expression levels underlying synucleinopathy spectrum disorders. This forthcoming knowledge will support the development of precision medicine for synucleinopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90:11282–11286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Galvin JE, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186–190

    Article  CAS  PubMed  Google Scholar 

  3. Marti MJ, Tolosa E, Campdelacreu J (2003) Clinical overview of the synucleinopathies. Mov Disord 18(Suppl 6):S21–S27. doi:10.1002/mds.10559

    Article  PubMed  Google Scholar 

  4. Spillantini MG (1999) Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 5:157–162

    Article  CAS  PubMed  Google Scholar 

  5. Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18(Suppl 6):S2–12. doi:10.1002/mds.10557

    Article  PubMed  Google Scholar 

  6. Goedert M, Jakes R, Anthony Crowther R, Grazia Spillantini M (2001) Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy as alpha-synucleinopathies. Methods Mol Med 62:33–59. doi:10.1385/1-59259-142-6:33

    CAS  PubMed  Google Scholar 

  7. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840

    Article  CAS  PubMed  Google Scholar 

  8. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047

    Article  CAS  PubMed  Google Scholar 

  9. Han W, Liu Y, Mi Y, Zhao J, Liu D, Tian Q (2015) Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson’s disease: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B:123–134. doi:10.1002/ajmg.b.32288

    Article  PubMed  CAS  Google Scholar 

  10. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, Psg P, GenePd Investigators C, Molecular Genetic L (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124:593–605. doi:10.1007/s00439-008-0582-9

    Article  CAS  PubMed  Google Scholar 

  11. Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ (2008) Multiple alpha-synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population. Acta Neurol Scand 118:320–327

    Article  CAS  PubMed  Google Scholar 

  12. Ross OA, Gosal D, Stone JT, Lincoln SJ, Heckman MG, Irvine GB, Johnston JA, Gibson JM, Farrer MJ, Lynch T (2007) Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson’s disease. Mech Ageing Dev 128:378–382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, Farrer MJ (2004) Alpha-synuclein promoter confers susceptibility to Parkinson’s disease. Ann Neurol 56:591–595

    Article  CAS  PubMed  Google Scholar 

  14. Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, Berg D, Wullner U, Meitinger T, Gasser T (2005) Multiple regions of alpha-synuclein are associated with Parkinson’s disease. Ann Neurol 57:535–541

    Article  CAS  PubMed  Google Scholar 

  15. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y, Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T (2006) Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson’s disease. Hum Mol Genet 15:1151–1158

    Article  CAS  PubMed  Google Scholar 

  16. Winkler S, Hagenah J, Lincoln S, Heckman M, Haugarvoll K, Lohmann-Hedrich K, Kostic V, Farrer M, Klein C (2007) {alpha}-synuclein and Parkinson disease susceptibility. Neurology 69:1745–50

  17. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41:1303–1307

    Article  CAS  PubMed  Google Scholar 

  18. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41:1308–1312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM, Martin ER (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. doi:10.1111/j.1469-1809.2009.00560.x

    PubMed Central  Google Scholar 

  20. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. Jama 296:661–670

    Article  CAS  PubMed  Google Scholar 

  21. CC S, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, RA B, Bellenguez C, Bhatia K, Blackburn H, JM B, Bramon E, MA B, Burn D, JP C, PF C, CE C, Corvin A, Craddock N, Deloukas P, Edkins S, Evans J, Freeman C, Gray E, Hardy J, Hudson G, Hunt S, Jankowski J, Langford C, AJ L, HS M, CG M, MI MC, KE M, CN P, JP P, Peltonen L, Pirinen M, Plomin R, Potter S, Rautanen A, SJ S, Z S, RC T, AC V, NW W, HR M, Donnelly P, NW W (2010) Dissection of the genetics of Parkinson’s disease identifies an additional association 5’ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 20:345–353. doi:10.1093/hmg/ddq469

    Google Scholar 

  22. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW, Arepalli S, Hernandez DG, de Bie RM, Velseboer D, Scheffer H, Bloem B, van Dijk KD, Rivadeneira F, Hofman A, Uitterlinden AG, Rizzu P, Bochdanovits Z, Singleton AB, Heutink P (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet. doi:10.1038/ejhg.2010.254

    PubMed  PubMed Central  Google Scholar 

  23. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67:1350–1356. doi:10.1001/archneurol.2010.279

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, Halliday GM, Mann D, Pickering-Brown S, Dickson DW, Singleton A, Hardy J (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 23:6139–6146. doi:10.1093/hmg/ddu334

    Article  PubMed  PubMed Central  Google Scholar 

  25. Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wullner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65:610–614

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Al-Chalabi A, Durr A, Wood NW, Parkinson MH, Camuzat A, Hulot JS, Morrison KE, Renton A, Sussmuth SD, Landwehrmeyer BG, Ludolph A, Agid Y, Brice A, Leigh PN, Bensimon G, Group NGS (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS one 4:e7114. doi:10.1371/journal.pone.0007114

    Article  CAS  Google Scholar 

  27. Linnertz C, Lutz MW, Ervin JF, Allen J, Miller NR, Welsh-Bohmer KA, Roses AD, Chiba-Falek O (2014) The genetic contributions of SNCA and LRRK2 genes to Lewy body pathology in Alzheimer’s disease. Hum Mol Genet 23:4814–4821. doi:10.1093/hmg/ddu196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lutz MW, Saul R, Linnertz C, Glenn OC, Roses AD, Chiba-Falek O (2015) A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer’s disease and affects SNCA expression. Alzheimer’s Dementia: J Alzheimer’s Assoc. doi:10.1016/j.jalz.2015.05.011

    Google Scholar 

  29. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18:106–108

    Article  CAS  PubMed  Google Scholar 

  30. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173

    Article  CAS  PubMed  Google Scholar 

  31. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302:841

    Article  CAS  PubMed  Google Scholar 

  32. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9:2683–2689

    Article  CAS  PubMed  Google Scholar 

  33. Banerjee K, Munshi S, Sen O, Pramanik V, Roy Mukherjee T, Chakrabarti S (2014) Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson’s disease. Parkinsons Dis 2014:878935. doi:10.1155/2014/878935

    PubMed  PubMed Central  Google Scholar 

  34. Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L (2009) Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J Neurochem 109:1348–1362. doi:10.1111/j.1471-4159.2009.06054.x

    Article  CAS  PubMed  Google Scholar 

  35. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 866:33–43

    Article  CAS  PubMed  Google Scholar 

  36. Taguchi K, Watanabe Y, Tsujimura A, Tatebe H, Miyata S, Tokuda T, Mizuno T, Tanaka M (2014) Differential expression of alpha-synuclein in hippocampal neurons. PLoS one 9:e89327. doi:10.1371/journal.pone.0089327

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Koch JC, Bitow F, Haack J, d’Hedouville Z, Zhang JN, Tonges L, Michel U, Oliveira LM, Jovin TM, Liman J, Tatenhorst L, Bahr M, Lingor P (2015) Alpha-synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis 6:e1811. doi:10.1038/cddis.2015.169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, Park CH, Kim S, Kim EM, Lee SH, Lee S, Suh SW, Suh YH (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 16:1826–1828. doi:10.1096/fj.02-0041fje

    CAS  PubMed  Google Scholar 

  39. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606. doi:10.1038/nm0602-600

    Article  CAS  PubMed  Google Scholar 

  40. Junn E, Mouradian MM (2002) Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 320:146–150

    Article  CAS  PubMed  Google Scholar 

  41. May VE, Ettle B, Poehler AM, Nuber S, Ubhi K, Rockenstein E, Winner B, Wegner M, Masliah E, Winkler J (2014) Alpha-synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging 35:2357–2368. doi:10.1016/j.neurobiolaging.2014.02.028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T (2011) Parkinson’s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2:440. doi:10.1038/ncomms1453

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Byers B, Cord B, Nguyen HN, Schule B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, Palmer TD (2011) SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS one 6:e26159. doi:10.1371/journal.pone.0026159

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Byers B, Lee HL, Reijo Pera R (2012) Modeling Parkinson’s disease using induced pluripotent stem cells. Current Neurol Neurosci Rep 12:237–242. doi:10.1007/s11910-012-0270-y

    Article  CAS  Google Scholar 

  45. Flierl A, Oliveira LM, Falomir-Lockhart LJ, Mak SK, Hesley J, Soldner F, Arndt-Jovin DJ, Jaenisch R, Langston JW, Jovin TM, Schule B (2014) Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. PLoS one 9:e112413. doi:10.1371/journal.pone.0112413

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Oliveira LM, Falomir-Lockhart LJ, Botelho MG, Lin KH, Wales P, Koch JC, Gerhardt E, Taschenberger H, Outeiro TF, Lingor P, Schule B, Arndt-Jovin DJ, Jovin TM (2015) Elevated alpha-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson’s patient-derived induced pluripotent stem cells. Cell Death Dis 6:e1994. doi:10.1038/cddis.2015.318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, Frisen J, Deierborg T, Roybon L (2015) Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Reports 5:174–184. doi:10.1016/j.stemcr.2015.07.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Crompton LA, Byrne ML, Taylor H, Kerrigan TL, Bru-Mercier G, Badger JL, Barbuti PA, Jo J, Tyler SJ, Allen SJ, Kunath T, Cho K, Caldwell MA (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. Stem Cell Res 11:1206–1221. doi:10.1016/j.scr.2013.08.002

    Article  CAS  PubMed  Google Scholar 

  49. Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, Lopez-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 4:380–395. doi:10.1002/emmm.201200215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Moskalev AA, Shaposhnikov MV, Plyusnina EN, Zhavoronkov A, Budovsky A, Yanai H, Fraifeld VE (2013) The role of DNA damage and repair in aging through the prism of Koch-like criteria. Ageing Res Rev 12:661–684. doi:10.1016/j.arr.2012.02.001

    Article  CAS  PubMed  Google Scholar 

  51. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239–247. doi:10.1038/35041687

    Article  CAS  PubMed  Google Scholar 

  52. Le W, Sayana P, Jankovic J (2014) Animal models of Parkinson’s disease: a gateway to therapeutics? Neurotherapeutics 11:92–110. doi:10.1007/s13311-013-0234-1

    Article  CAS  PubMed  Google Scholar 

  53. Deng H, Yuan L (2014) Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev 15:161–176. doi:10.1016/j.arr.2014.04.002

    Article  CAS  PubMed  Google Scholar 

  54. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, Blakely RD, Wong G (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86:165–172

    Article  CAS  PubMed  Google Scholar 

  55. Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease. Nature 404:394–398

    Article  CAS  PubMed  Google Scholar 

  56. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson’s disease. J Neurochem 91:451–461. doi:10.1111/j.1471-4159.2004.02728.x

    Article  CAS  PubMed  Google Scholar 

  57. Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schonig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Muller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O (2013) A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain 136:412–432. doi:10.1093/brain/aws358

    Article  PubMed  PubMed Central  Google Scholar 

  58. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265–1269

    Article  CAS  PubMed  Google Scholar 

  59. McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson’s disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49:230–239. doi:10.1016/j.mcn.2011.11.006

    Article  CAS  PubMed  Google Scholar 

  60. Subramaniam SR, Vergnes L, Franich NR, Reue K, Chesselet MF (2014) Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. Neurobiol Dis 70:204–213. doi:10.1016/j.nbd.2014.06.017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26:5256–5264. doi:10.1523/JNEUROSCI.0984-06.2006

    Article  CAS  PubMed  Google Scholar 

  62. Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, Parkkinen L, Senior SL, Anwar S, Ryan B, Deltheil T, Kosillo P, Cioroch M, Wagner K, Ansorge O, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Wade-Martins R (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A 110:E4016–E4025. doi:10.1073/pnas.1309143110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee VM (2005) Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847–859. doi:10.1016/j.neuron.2005.01.032

    Article  CAS  PubMed  Google Scholar 

  64. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, Wenning GK (2005) Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166:869–876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease. Proc Natl Acad Sci U S A 100:2884–2889. doi:10.1073/pnas.0536383100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68:916–922

    Article  CAS  PubMed  Google Scholar 

  67. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ (2008) Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 63:743–750

    Article  CAS  PubMed  Google Scholar 

  68. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364:1167–1169

    Article  CAS  PubMed  Google Scholar 

  69. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet 364:1169–1171

    Article  CAS  PubMed  Google Scholar 

  70. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55:174–179

    Article  CAS  PubMed  Google Scholar 

  71. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62:1835–1838

    Article  CAS  PubMed  Google Scholar 

  72. Chiba-Falek O, Lopez GJ, Nussbaum RL (2006) Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 21:1703–1708. doi:10.1002/mds.21007

    Article  PubMed  Google Scholar 

  73. Grundemann J, Schlaudraff F, Haeckel O, Liss B (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res 36:e38

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E (2001) Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease. Brain Res 914:48–56

    Article  CAS  PubMed  Google Scholar 

  75. Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, Houlden H, Holton JL (2014) Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62:964–970. doi:10.1002/glia.22653

    Article  PubMed  PubMed Central  Google Scholar 

  76. Lutz MW, Saul R, Linnertz C, Glenn OC, Roses AD, Chiba-Falek O (2015) A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer’s disease and affects SNCA expression. Alzheimers Dement 11:1133–1143. doi:10.1016/j.jalz.2015.05.011

    Article  PubMed  Google Scholar 

  77. Neystat M, Lynch T, Przedborski S, Kholodilov N, Rzhetskaya M, Burke RE (1999) Alpha-synuclein expression in substantia nigra and cortex in Parkinson’s disease. Mov Disord 14:417–422

    Article  CAS  PubMed  Google Scholar 

  78. Kingsbury AE, Daniel SE, Sangha H, Eisen S, Lees AJ, Foster OJ (2004) Alteration in alpha-synuclein mRNA expression in Parkinson’s disease. Mov Disord 19:162–170

    Article  PubMed  Google Scholar 

  79. Tan EK, Chandran VR, Fook-Chong S, Shen H, Yew K, Teoh ML, Yuen Y, Zhao Y (2005) Alpha-synuclein mRNA expression in sporadic Parkinson’s disease. Mov Disord 20:620–623

    Article  PubMed  Google Scholar 

  80. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm (Vienna) 113:1435–1439. doi:10.1007/s00702-005-0427-9

    Article  CAS  Google Scholar 

  81. Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, Masters CL, Culvenor JG, Horne MK (2007) Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease. Exp Neurol 204:583–588. doi:10.1016/j.expneurol.2006.12.006

    Article  CAS  PubMed  Google Scholar 

  82. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett 480:78–82. doi:10.1016/j.neulet.2010.06.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Chu Y, Kordower JH (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson’s disease? Neurobiol Dis 25:134–149. doi:10.1016/j.nbd.2006.08.021

    Article  CAS  PubMed  Google Scholar 

  84. Obeso JA (2010) Modeling clinical features of neurodegeneration. Nat Med 16:1372. doi:10.1038/nm1210-1372b

    Article  CAS  PubMed  Google Scholar 

  85. Collier TJ, Kanaan NM, Kordower JH (2011) Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat Rev Neurosci 12:359–366. doi:10.1038/nrn3039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Fountaine TM, Venda LL, Warrick N, Christian HC, Brundin P, Channon KM, Wade-Martins R (2008) The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur J Neurosci 28:2459–2473. doi:10.1111/j.1460-9568.2008.06527.x

    Article  PubMed  PubMed Central  Google Scholar 

  87. Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle K, Kent C, Toudjarska I, Charisse K, Braich R, Pandey RK, Heckman M, Maraganore DM, Crook J, Farrer MJ (2008) In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 3:19

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Gorbatyuk OS, Li S, Nash K, Gorbatyuk M, Lewin AS, Sullivan LF, Mandel RJ, Chen W, Meyers C, Manfredsson FP, Muzyczka N (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther J. Am Soc Gene Ther 18:1450–1457. doi:10.1038/mt.2010.115

    Article  CAS  Google Scholar 

  89. Liu D, Jin L, Wang H, Zhao H, Zhao C, Duan C, Lu L, Wu B, Yu S, Chan P, Li Y, Yang H (2008) Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem Res 33:1401–1409. doi:10.1007/s11064-008-9599-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Han Y, Khodr CE, Sapru MK, Pedapati J, Bohn MC (2011) A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res 1386:15–24. doi:10.1016/j.brainres.2011.02.041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA (2010) Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS one 5:e12122. doi:10.1371/journal.pone.0012122

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Takahashi M, Suzuki M, Fukuoka M, Fujikake N, Watanabe S, Murata M, Wada K, Nagai Y, Hohjoh H (2015) Normalization of overexpressed alpha-synuclein causing Parkinson’s disease by a moderate gene silencing with RNA interference. Molecular Therapy Nucleic Acids 4:e241. doi:10.1038/mtna.2015.14

    Article  PubMed  Google Scholar 

  93. Khodr CE, Sapru MK, Pedapati J, Han Y, West NC, Kells AP, Bankiewicz KS, Bohn MC (2011) An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson’s disease, but displays toxicity in dopamine neurons. Brain Res 1395:94–107. doi:10.1016/j.brainres.2011.04.036

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Chiba-Falek O, Kowalak JA, Smulson ME, Nussbaum RL (2005) Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet 76:478–492

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, Schlossmacher MG (2008) GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 105:10907–10912. doi:10.1073/pnas.0802437105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Clough RL, Dermentzaki G, Stefanis L (2009) Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J Neurochem 110:1479–1490. doi:10.1111/j.1471-4159.2009.06250.x

    Article  CAS  PubMed  Google Scholar 

  97. Brenner S, Wersinger C, Gasser T (2015) Transcriptional regulation of the alpha-synuclein gene in human brain tissue. Neurosci Lett 599:140–145. doi:10.1016/j.neulet.2015.05.029

    Article  CAS  PubMed  Google Scholar 

  98. Clough RL, Stefanis L (2007) A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J 21:596–607. doi:10.1096/fj.06-7111com

    Article  CAS  PubMed  Google Scholar 

  99. Clough RL, Dermentzaki G, Haritou M, Petsakou A, Stefanis L (2011) Regulation of alpha-synuclein expression in cultured cortical neurons. J Neurochem 117:275–285. doi:10.1111/j.1471-4159.2011.07199.x

    Article  CAS  PubMed  Google Scholar 

  100. Sterling L, Walter M, Ting D, Schule B (2014) Discovery of functional non-coding conserved regions in the alpha-synuclein gene locus. F1000Res 3:259. doi:10.12688/f1000research.3281.2

    PubMed  PubMed Central  Google Scholar 

  101. Doxakis E (2010) Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 285:12726–12734. doi:10.1074/jbc.M109.086827

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20:3067–3078. doi:10.1093/hmg/ddr210

    Article  CAS  PubMed  Google Scholar 

  103. Villar-Menendez I, Porta S, Buira SP, Pereira-Veiga T, Diaz-Sanchez S, Albasanz JL, Ferrer I, Martin M, Barrachina M (2014) Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b. Neurobiol Dis 69:206–214. doi:10.1016/j.nbd.2014.05.030

    Article  CAS  PubMed  Google Scholar 

  104. Kabaria S, Choi DC, Chaudhuri AD, Mouradian MM, Junn E (2015) Inhibition of miR-34b and miR-34c enhances alpha-synuclein expression in Parkinson’s disease. FEBS Lett 589:319–325. doi:10.1016/j.febslet.2014.12.014

    Article  CAS  PubMed  Google Scholar 

  105. Xu W, Tan L, Yu JT (2015) The link between the SNCA gene and parkinsonism. Neurobiol Aging 36:1505–1518. doi:10.1016/j.neurobiolaging.2014.10.042

    Article  CAS  PubMed  Google Scholar 

  106. Kalivendi SV, Yedlapudi D, Hillard CJ, Kalyanaraman B (2010) Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson’s disease. Free Radic Biol Med 48:377–383. doi:10.1016/j.freeradbiomed.2009.10.045

    Article  CAS  PubMed  Google Scholar 

  107. Beyer K, Domingo-Sabat M, Humbert J, Carrato C, Ferrer I, Ariza A (2008) Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 9:163–172

    Article  CAS  PubMed  Google Scholar 

  108. Beyer K (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 112:237–251

    Article  CAS  PubMed  Google Scholar 

  109. Lee HJ, Choi C, Lee SJ (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem 277:671–678

    Article  CAS  PubMed  Google Scholar 

  110. Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I, Ariza A (2004) Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 30:601–607. doi:10.1111/j.1365-2990.2004.00572.x

    Article  CAS  PubMed  Google Scholar 

  111. Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, Lopez D, Ferrer I, Ariza A (2006) Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 17:1327–1330. doi:10.1097/01.wnr.0000224773.66904.e7

    Article  CAS  PubMed  Google Scholar 

  112. Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, Ariza A (2008) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9:15–23

    Article  PubMed  Google Scholar 

  113. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31:14508–14520. doi:10.1523/JNEUROSCI.1560-11.2011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Ward WF (2002) Protein degradation in the aging organism. Prog Mol Subcell Biol 29:35–42

    Article  CAS  PubMed  Google Scholar 

  115. Xilouri M, Brekk OR, Stefanis L (2013) Alpha-synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 47:537–551. doi:10.1007/s12035-012-8341-2

    Article  CAS  PubMed  Google Scholar 

  116. Xia Y, Rohan de Silva HA, Rosi BL, Yamaoka LH, Rimmler JB, Pericak-Vance MA, Roses AD, Chen X, Masliah E, DeTeresa R, Iwai A, Sundsmo M, Thomas RG, Hofstetter CR, Gregory E, Hansen LA, Katzman R, Thal LJ, Saitoh T (1996) Genetic studies in Alzheimer’s disease with an NACP/alpha-synuclein polymorphism. Ann Neurol 40:207–215

    Article  CAS  PubMed  Google Scholar 

  117. Touchman JW, Dehejia A, Chiba-Falek O, Cabin DE, Schwartz JR, Orrison BM, Polymeropoulos MH, Nussbaum RL (2001) Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res 11:78–86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Chiba-Falek O, Nussbaum RL (2001) Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 10:3101–3109

    Article  CAS  PubMed  Google Scholar 

  119. Goldman SM, Umbach DM, Kamel F, Tanner CM (2015) Head injury, alpha-synuclein Rep1 and Parkinson’s disease: a meta-analytic view of gene-environment interaction. Eur J Neurol 22:e75. doi:10.1111/ene.12694

    Article  CAS  PubMed  Google Scholar 

  120. Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, Leis BC, Nutt JG, Montimurro JS, Keefe RG, Atkins AJ, Yearout D, Zabetian CP, Payami H (2008) Genetic association between alpha-synuclein and idiopathic Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 147B:1222–1230

    Article  PubMed  Google Scholar 

  121. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, West A, de Silva R, Hardy J, Hernandez D (2001) Alpha-synuclein gene haplotypes are associated with Parkinson’s disease. Hum Mol Genet 10:1847–1851

    Article  CAS  PubMed  Google Scholar 

  122. Mizuta I, Nishimura M, Mizuta E, Yamasaki S, Ohta M, Kuno S (2002) Meta-analysis of alpha synuclein/NACP polymorphism in Parkinson’s disease in Japan. J Neurol Neurosurg Psychiatry 73:350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Mellick GD, Maraganore DM, Silburn PA (2005) Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson’s disease. Neurosci Lett 375:112–116

    Article  CAS  PubMed  Google Scholar 

  124. Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, Bernard DJ, El-Agnaf OM, Schlossmacher MG, Nussbaum RL, Chiba-Falek O (2009) Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 18:3274–3285. doi:10.1093/hmg/ddp265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Linnertz C, Saucier L, Ge D, Cronin KD, Burke JR, Browndyke JN, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O (2009) Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS one 4:e7480. doi:10.1371/journal.pone.0007480

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Beyer K, Humbert J, Ferrer A, Lao JI, Latorre P, Lopez D, Tolosa E, Ferrer I, Ariza A (2007) A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging. J Neurosci Res 85:1538–1546. doi:10.1002/jnr.21270

    Article  CAS  PubMed  Google Scholar 

  127. McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O (2011) The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant. Neurogenetics 12:59–64. doi:10.1007/s10048-010-0263-4

    Article  CAS  PubMed  Google Scholar 

  128. Sotiriou S, Gibney G, Baxevanis AD, Nussbaum RL (2009) A single nucleotide polymorphism in the 3′UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 461:196–201. doi:10.1016/j.neulet.2009.06.034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Kruger R, Vieira-Saecker AM, Kuhn W, Berg D, Muller T, Kuhnl N, Fuchs GA, Storch A, Hungs M, Woitalla D, Przuntek H, Epplen JT, Schols L, Riess O (1999) Increased susceptibility to sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 45:611–617

    Article  CAS  PubMed  Google Scholar 

  130. McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H (2008) Exploring gene-environment interactions in Parkinson’s disease. Hum Genet 123:257–265

    Article  CAS  PubMed  Google Scholar 

  131. Peuralinna T, Myllykangas L, Oinas M, Nalls MA, Keage HA, Isoviita VM, Valori M, Polvikoski T, Paetau A, Sulkava R, Ince PG, Zaccai J, Brayne C, Traynor BJ, Hardy J, Singleton AB, Tienari PJ (2015) Genome-wide association study of neocortical Lewy-related pathology. Ann Clin Transl Neurol 2:920–931. doi:10.1002/acn3.231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Kim WS, Kagedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimer’s Res Therapy 6:73. doi:10.1186/s13195-014-0073-2

    Article  CAS  Google Scholar 

  133. Chen Y, Wei QQ, Ou R, Cao B, Chen X, Zhao B, Guo X, Yang Y, Chen K, Wu Y, Song W, Shang HF (2015) Genetic variants of SNCA are associated with susceptibility to Parkinson’s disease but not amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. PLoS one 10:e0133776. doi:10.1371/journal.pone.0133776

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Ammal Kaidery N, Tarannum S, Thomas B (2013) Epigenetic landscape of Parkinson’s disease: emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics 10:698–708. doi:10.1007/s13311-013-0211-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Jowaed A, Schmitt I, Kaut O, Wullner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J Neurosci off J Soc Neurosci 30:6355–6359. doi:10.1523/JNEUROSCI.6119-09.2010

    Article  CAS  Google Scholar 

  136. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A (2010) CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS one 5:e15522. doi:10.1371/journal.pone.0015522

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  137. Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, Adame A, Rockenstein E, Masliah E (2011) Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem 286:9031–9037. doi:10.1074/jbc.C110.212589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Song Y, Ding H, Yang J, Lin Q, Xue J, Zhang Y, Chan P, Cai Y (2014) Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson’s disease patients. Neurosci Lett 569:85–88. doi:10.1016/j.neulet.2014.03.076

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. W.K. Gottschalk for the useful comments and discussions. This work was funded in part by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS; R01 NS085011 to O.C.).

Author information

Authors and Affiliations

  1. Department of Neurology, Duke University Medical Center, Durham, NC, 27710, USA

    L. Tagliafierro & O. Chiba-Falek

Authors
  1. L. Tagliafierro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Chiba-Falek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Chiba-Falek.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tagliafierro, L., Chiba-Falek, O. Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics 17, 145–157 (2016). https://doi.org/10.1007/s10048-016-0478-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10048-016-0478-0

Keywords

Search

Navigation